Clinical Research Centre - Ramaih Group

M S Ramaiah Medical College and Hospitals

Ulcer

Diabetes Mellitus

Hypertension

Colitis

Ulcerative Colitis

Type 2 Diabetes Mellitus

Communicable Diseases

Endocrine System Diseases

Metabolic Diseases

Psychological Stress

Mirikizumab

LY3298176

Avibactam

LY3502970

Aztreonam

Orforglipron

Meropenem

Tirzepatide

Lilly

MS Ramaiah Medical College & Hospitals

Pfizer

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

M S Ramaiah Medical College and Hospitals | Clinical Research Centre - Ramaih Group

Site insights

Work at this site?

Active trials

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Trial sponsors